Most pharma organisations believe they are compliant with consent requirements because consent exists somewhere in their systems. Under the Digital Personal Data Protection Act 2023, this belief is not enough. What matters is not whether consent exists, but whether consent is enforced at the exact moment engagement happens.

This distinction is critical.

DPDP shifts compliance from documentation to execution. Consent must actively control whether data can be used at the point of engagement. If a message is sent, an ad is targeted, or an interaction is triggered without real time consent validation, the organisation is exposed to risk.

This article explains what consent enforcement at the point of engagement truly means for pharma companies, why legacy workflows fail, and what must change across systems, teams, and execution models to meet DPDP expectations at scale.

Most pharma companies believe their CRM systems are ready for DPDP compliance. After all, consent fields exist, opt out flags are present, and suppression lists are maintained. On paper, this looks sufficient.

In practice, this belief is one of the biggest risks pharma organisations face under the Digital Personal Data Protection Act 2023.

CRMs were never designed to handle consent as DPDP defines it. They were built to support sales force efficiency, targeting, and reporting. Consent tracking was added later as a checkbox feature, not as a governing control layer.

This gap becomes painfully visible during audits, incidents, or consent withdrawal scenarios. This article explains why most pharma CRMs fail at consent tracking, what specifically breaks under DPDP, and how organisations must rethink consent architecture to remain compliant at scale.

Consent collection becomes significantly more complex when pharma marketing moves beyond a single channel. While many teams focus on capturing consent at a high level, real compliance challenges emerge during execution across email, WhatsApp, and digital advertising.

Each channel has different expectations, different risk profiles, and different operational realities. Under the Digital Personal Data Protection Act 2023, treating consent as uniform across channels is no longer defensible.

This article explains how pharma companies can design and operate DPDP-compliant consent collection across email, WhatsApp, and ads, without fragmenting workflows or slowing down engagement at scale.

Capturing explicit consent from doctors has become one of the most difficult operational challenges for pharma marketing teams under the Digital Personal Data Protection Act 2023. While the requirement itself is clear, the execution is not. Most existing systems, workflows, and engagement models were never designed to capture consent in a way that is explicit, purpose specific, auditable, and scalable.

Yet scale is unavoidable in pharma marketing. Engagement programs often involve thousands of doctors across geographies, specialties, and channels. Expecting manual consent collection or fragmented approaches is unrealistic.

This is where many teams struggle. They understand the legal requirement but cannot translate it into operational reality. This article explains how pharma companies can capture explicit consent from doctors at scale, without slowing down engagement or creating unmanageable complexity.

For years, opt in consent was treated as a sufficient safeguard in pharma marketing. If a doctor or patient opted in to receive communication, teams assumed they had the freedom to engage across channels and campaigns. Databases expanded, automation increased, and opt in records were rarely revisited.

The Digital Personal Data Protection Act 2023 makes this approach obsolete.

Under DPDP, opt in by itself does not meet the legal standard for consent. What once functioned as a practical shortcut now creates compliance risk. Understanding why opt in is no longer enough is essential for any pharma or healthcare organisation running digital engagement programs.

This article explains why opt in fails under DPDP, where legacy practices break down, and how marketing teams must redesign consent to operate safely and at scale.

Consent has always existed in pharma marketing, but the meaning of consent under the Digital Personal Data Protection Act 2023 is very different from how it was understood earlier. Many pharma teams still use the terms explicit consent and opt in interchangeably, assuming they represent the same thing.

Under DPDP, they do not.

This distinction is not semantic. It directly affects whether doctor and patient engagement programs are compliant, auditable, and defensible. Misunderstanding this difference is one of the most common reasons pharma marketing workflows fail DPDP requirements.

This article explains explicit consent versus opt in from a DPDP perspective, using real pharma marketing scenarios to show why older opt in models no longer work and how teams must adapt.

One of the most common sources of confusion under the Digital Personal Data Protection Act 2023 is the concept of the data principal. Pharma and healthcare teams often ask a simple but critical question: who exactly is the data principal in our workflows? Is it the doctor, the patient, or both?

The answer has direct consequences for consent collection, data usage, marketing execution, and compliance accountability. Misidentifying the data principal leads to flawed assumptions about whose consent is required, whose rights must be honoured, and where risk truly lies.

This article explains who qualifies as a data principal under DPDP using real pharma and healthcare data scenarios, and how teams must adapt their engagement models accordingly.

The Digital Personal Data Protection Act 2023 introduces a higher bar for organisations that process personal data at scale or in sensitive contexts. For healthcare and pharmaceutical companies, this often translates into being treated as significant data fiduciaries.

This classification is not merely descriptive. It brings enhanced compliance expectations that directly affect how healthcare data is governed, how marketing and engagement programs operate, and how technology systems are designed.

This article explains what compliance expectations look like for significant data fiduciaries in healthcare, why these expectations are higher, and how pharma companies must adapt their operations to meet them.

The Digital Personal Data Protection Act 2023 introduces an important concept that many pharma companies have not yet fully internalised: the idea of a Significant Data Fiduciary. While most organisations now recognise that they are data fiduciaries, fewer understand that many pharma companies are likely to be classified as significant data fiduciaries under DPDP.

This distinction is not symbolic. It brings additional compliance expectations, higher scrutiny, and stronger governance requirements. For pharma marketing, commercial, medical, and digital teams, this classification has real operational consequences.

This article explains what a significant data fiduciary is under DPDP, why most pharma companies meet this threshold, and how this changes accountability for doctor and patient data.

The term data fiduciary appears frequently in discussions around the Digital Personal Data Protection Act 2023, yet it remains poorly understood within pharma organisations. Many teams assume it is a legal classification with limited relevance to day-to-day marketing or doctor engagement activities.

In reality, data fiduciary status directly affects how doctor data is collected, stored, shared, and activated across pharma marketing workflows. It determines who is accountable when consent is missing, when data is misused, or when audits occur.

This article explains the meaning of data fiduciary under DPDP Act using doctor data as the central example, because doctor engagement represents one of the most common and risk-exposed data use cases in pharma.